Zydus group enters into in-licensing deal with Neovii
New Delhi : Ahmedabad based Zydus Group has entered into an in-licensing agreement with Switzerland-based Neovii to launch Grafalon, an immuno suppressant used in solid organ transplants and stem cell transplants, in India.
“The Zydus group will market this therapy through Zydus Trans immune, a division that offers a range of therapies related to transplant medicine,” group firm Cadila Healthcare said in a filing to the BSE.
Grafalon offers a specific advantage of efficacy and better safety profile through targeted immuno-suppression, it added.
“More than 200,000 patients till date, in over 50 countries, have been treated with Grafalon,” Cadila Healthcare said.
Transplant outcomes can be improved significantly by the use of immuno suppressant drugs like Grafalon, it added.
“Currently, an estimated 10,000 solid organ transplants and stem cell transplants are taking place annually across 200 plus transplant centres in India,” the company said.
Cadila Healthcare stock ended the session down by 0.89 per cent at Rs. 385.15 on the BSE.